Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Core Insights - Prime Medicine, Inc. is focused on advanced gene-editing technology through its proprietary Prime Editing platform, which aims to provide one-time therapeutic solutions for diseases with limited treatment options [1] Company Overview - The company is developing a pipeline that includes its leading candidate, PM359, which is indicated for chronic granulomatous disease [1]